Biotech Blueprint
Substacknewsletter · by Biotech Blueprint · English
- Audience
- 7K subscribers
- Shown publicly on Substack
- Publishing
- Every two weeks
- 5 posts indexed in the last 90 days
- Last post
- Oct 16, 2026
- 14 days ago
- Likely audience
- Biotech investors
- Inferred from post content
Biotech Blueprint is a Substack newsletter by Biotech Blueprint covering FDA regulatory policy, AI in drug discovery and Phase 3 clinical trial results. NewsletterFIT indexed 5 posts from it in the last 90 days, most recently on Oct 16, 2026. Shown publicly on Substack: 7K subscribers.
Topics
- FDA regulatory policy
- AI in drug discovery
- Phase 3 clinical trial results
- Diabetic macular edema treatment
- Idiopathic pulmonary fibrosis
Recent posts
- Merck paid…
- Vaxcyte’s pneumococcal…
- AstraZeneca spent…
- Four phase…
- The best…
Sponsors detected
No sponsored posts detected in the last 180 days of indexed posts.
Detected automatically from posts marked as sponsored. Detection can miss or misread placements.
See the full picture on Biotech Blueprint
Subscriber momentum over time, every detected sponsor with the source post, companies and people it mentions, guests, and an alert when any of it changes.
Similar newsletters
Ranked by how many topics they share with Biotech Blueprint.
- Where Tech Meets Bio12K subscribers
SubstackEvery two weeks · last post 8 days ago
Likely audience: Venture capitalists
1 shared topic
- Deep Phenotype, a Substack by insitro 2K subscribers
SubstackMonthly or less · last post Aug 28, 2026
Likely audience: Science researchers
1 shared topic
LinkedInMonthly or less · last post 17 days ago
Likely audience: Life sciences researchers
1 shared topic
Compiled from public pages · refreshed Oct 21, 2026 · How NewsletterFIT collects and labels data